Certified for Global Markets, the Domestic MCT Solution Addresses Pharma Supply Chain Gaps
【Guangzhou, China】– 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical excipients and active pharmaceutical ingredients (APIs), today announces the full-scale commercialization of its medium chain triglycerides (MCT) specifically formulated for fat emulsion applications. This product breaks the long-term global monopoly on high-end MCT for pharmaceutical use, raising domestic substitution rates from 10% to 90% through independent technological innovation. Equipped with green manufacturing processes and international certifications, Hanfang’s MCT is designed to address supply chain vulnerabilities for pharmaceutical enterprises worldwide, with global availability starting immediately.
Core Technological Breakthroughs & Product Advantages
Hanfang’s MCT leverages an integrated green technology platform combining supercritical CO₂ extraction, membrane separation, and chromatographic separation, replacing traditional pollution-heavy production methods. This innovative process ensures high purity and consistency, meeting strict pharmaceutical quality standards. As of 2025, the company holds over 240 patents, underscoring its technical barriers in the pharmaceutical lipid excipient sector. The product is specifically optimized for fat emulsion formulations, enhancing stability and bioavailability while reducing production costs for clients.
Global Compliance & Certifications
To meet global market access requirements, Hanfang’s MCT has obtained key international certifications including EU CEP and US FDA US-DMF, alongside approvals from Mexico Cofepris and India DCGI. These certifications confirm the product’s compliance with regulatory standards across major markets in Europe, North America, and Asia-Pacific, enabling seamless integration into global pharmaceutical supply chains.
Supply & Customization Services
Hanfang’s MCT is now available for global orders through its official website and authorized distributors, with full-scale production and shipment underway. Beyond standard products, the company offers tailored customization services including formulation adjustments and processing modifications, catering to the diverse needs of pharmaceutical, nutraceutical, and specialty food enterprises.
Authoritative Quotes
"Our MCT product represents a significant milestone in advancing domestic high-end pharmaceutical excipients, effectively resolving long-standing supply chain challenges for global partners," said Xu Wendong, General Manager of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "As a leader in pharmaceutical lipid technology, we remain committed to driving technological self-reliance and providing reliable, sustainable solutions to support the global healthcare industry."
Industry Context & Corporate Strategy
The global pharmaceutical excipient market is experiencing steady growth, fueled by rising demand for safe, high-quality raw materials in parenteral nutrition and fat-based drug delivery systems. Hanfang’s launch of domestically produced MCT aligns with the industry’s shift toward localized supply chains, offering a cost-effective and secure alternative to imported products.
Future Plans
Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to invest in R&D for pharmaceutical lipid excipients, expanding its product portfolio to meet evolving global market needs. The company also plans to strengthen its global distribution network, providing localized technical support and services to clients in more regions.
Company Profile
Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. was founded in 1998 as a core enterprise under the Guangzhou Pharmaceutical Holdings Group. It operates the only national engineering research center for traditional Chinese medicine processing technology, alongside provincial-level R&D platforms. The company serves over 1,000 global clients including B. Braun and AstraZeneca, with products available in more than 20 countries. Its mission is to achieve technological self-reliance, secure pharmaceutical supply chains, and protect human health.
Contact Information
Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/
© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.
